Track Trevi Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Trevi Therapeutics, Inc. TRVI · Stock Open Trevi Therapeutics, Inc. in new tab

13.65 USD
EPS
-0.35
P/B
6.74
ROE
-24.67
Beta
1.12
Target Price
28.18 USD
Loading chart...
Key Metrics
Earnings dateMarch 16, 2027
EPS-0.35
Book Value2.12
Price to Book6.74
Debt/Equity0.17
% Insiders0.628%
Estimates
Forward P/E-24.17
Forward EPS-0.59
Target Mean Price28.18

DCF valuation

Model fair value for Trevi Therapeutics, Inc. (TRVI)
Result
Sign in to run the valuation for TRVI.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
11 analysts · consensus Strong buy · mean target 28.18 USD (low 23.00, high 40.00) · as of 10 Nov 2026
Low 23.00
Mean 28.18
High 40.00
Price 13.65
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Trevi Therapeutics, Inc. Logo Trevi Therapeutics, Inc. Analysis (TRVI)

United States Health Care Official Website Stock

Is Trevi Therapeutics, Inc. a good investment? Trevi Therapeutics, Inc. (TRVI) is currently trading at 13.65 USD. Market analysts have a consensus price target of 28.18 USD. This suggests a potential upside from current levels.

Earnings Schedule: Trevi Therapeutics, Inc. is expected to release its next earnings report on March 16, 2027. The market consensus estimate for Forward EPS is -0.59.

Investor FAQ

Does Trevi Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Trevi Therapeutics, Inc.?

Trevi Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 16, 2027. The company currently has a trailing EPS of -0.35.

Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Exchange Ticker
NMS (United States) TRVI
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion